MarketCapExport financials
Syros Pharmaceuticals (SYRS)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Syros Pharmaceuticals Financial Ratios 2023-2011 | SYRS
Brief overview of Syros Pharmaceuticals's valuation and returns
The review covers five available annual periods spanning 2014 to 2022.
The latest available valuation ratios are EV/EBITDA 0.91x (median 0.91x), P/S 16.65x (median 3.09x), P/B 0.98x (median 0.19x). Multiples are on average 423% above their own medians. A substantial share of positive expectations may already be priced in.
End-period return metrics are ROE -9.9%, ROA -97.9%, ROCE -7.7%. The business is not generating positive returns on invested resources. Valuation should be read cautiously until earnings recover.
PEG is 0.27x. Price is low relative to embedded growth, though the ratio depends heavily on forecast quality.
The time from paying for inputs to receiving cash fell from 499.1 days to 0.1 days. Cash turnover improved.
Overall assessment
Syros Pharmaceuticals's profile looks stretched: price anticipates improvement that current quality ratios do not yet confirm.
Annual Financial Ratios Syros Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-1.0 | -0.5 | -0.1 | -0.5 | -3.1 | -3.6 | -5.0 | -2.9 | - | - | - | - | - |
P/S |
16.6 | 3.1 | 0.3 | 2.6 | 463.2 | 248.3 | 243.2 | 442.6 | - | - | - | - | - |
EPS |
-5.8 | -7.5 | -13.8 | -18.2 | -1.9 | -1.9 | -2.1 | -4.0 | -17.6 | -10.3 | - | - | - |
EV (Enterprise Value) |
25.9 M | -121 M | -84.2 M | -135 M | 265 M | 200 M | 249 M | 92.4 M | -26.3 M | -59.1 M | - | - | - |
EBITDA per Share |
-4.47 | -10.5 | -15.5 | -17.3 | -1.87 | -1.92 | -2.09 | -3.68 | -14.8 | -8.64 | - | - | - |
EV/EBITDA |
-0.2 | 0.9 | 0.9 | 1.7 | -3.5 | -3.2 | -4.7 | -2.0 | 0.9 | 4.5 | - | - | - |
PEG |
-0.01 | -0.0 | -0.0 | -0.0 | 0.27 | -0.29 | -0.1 | 0.03 | - | - | - | - | - |
P/B |
1.0 | 0.2 | 0.0 | 0.2 | 3.0 | 2.8 | 4.1 | 1.7 | - | - | - | - | - |
P/CF |
-1.5 | -0.4 | -0.1 | -0.7 | -3.9 | -5.5 | -6.0 | -3.5 | - | - | - | - | - |
ROE % |
-987.72 | -74.10 | -101.57 | -92.81 | -95.27 | -79.25 | -82.68 | -59.23 | 62.17 | 61.69 | - | - | - |
ROA % |
-97.86 | -38.72 | -47.32 | -39.41 | -50.30 | -58.33 | -68.81 | -52.28 | -68.34 | -21.84 | - | - | - |
ROCE % |
-774.14 | -106.37 | -116.67 | -90.88 | -61.47 | -73.70 | -82.76 | -58.67 | 64.35 | 61.71 | - | - | - |
Current Ratio |
- | - | - | - | 2.1 | 3.8 | 6.0 | 8.5 | 4.6 | 49.1 | - | - | - |
DSO |
- | - | 0.1 | 241.9 | 7185.0 | - | 143.7 | 499.1 | - | - | - | - | - |
Operating Cycle |
- | - | 0.1 | 241.9 | 7185.0 | - | 143.7 | 499.1 | - | - | - | - | - |
Cash Conversion Cycle |
- | - | 0.1 | 241.9 | 7185.0 | - | 143.7 | 499.1 | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Syros Pharmaceuticals
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.16 | -0.59 | -0.1 | - | -1.43 | -1.3 | -0.85 | - | -3.21 | -0.54 | -0.4 | - | -0.41 | -0.36 | -0.23 | -0.62 | -0.43 | -0.38 | -0.39 | -0.46 | -0.47 | -0.47 | -0.49 | -0.54 | -0.47 | -0.43 | -0.48 | -0.58 | -0.53 | -0.52 | -0.49 | -0.47 | -0.65 | -5.42 | -5.15 | -5.14 | -4.51 | -4.16 | -3.44 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.64 | -0.68 | -0.78 | - | -1.17 | -1.17 | -1.17 | - | -3.98 | -0.51 | -0.41 | - | -0.4 | -0.39 | -0.33 | -0.6 | -0.37 | -0.34 | -0.38 | -0.47 | -0.44 | -0.46 | -0.49 | -0.55 | -0.45 | -0.42 | -0.48 | -0.59 | -0.49 | -0.5 | -0.48 | -0.47 | -0.6 | -4.48 | -4.31 | -4.61 | -3.76 | -3.36 | -2.72 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
289.53 | 182.53 | -207.00 | -182.37 | -205.79 | -206.37 | -196.94 | -174.66 | -199.20 | -193.08 | -91.41 | -51.34 | -84.61 | -102.49 | -112.74 | -125.75 | -117.39 | -95.90 | -85.73 | -88.94 | -86.97 | -82.64 | -78.17 | -66.30 | -66.78 | -67.78 | -69.53 | -72.11 | -62.29 | -60.31 | -28.06 | -70.82 | -34.93 | 42.81 | 87.37 | 22.29 | 62.13 | 62.13 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-59.30 | -71.81 | -61.53 | -58.78 | -69.41 | -69.56 | -66.06 | -54.48 | -66.99 | -65.98 | -44.13 | -27.59 | -41.72 | -43.82 | -45.84 | -51.05 | -50.08 | -49.22 | -50.40 | -58.34 | -62.08 | -61.36 | -59.24 | -51.92 | -54.52 | -57.07 | -59.88 | -63.34 | -55.85 | -54.38 | -60.60 | -98.07 | -110.57 | -164.75 | -213.33 | -24.50 | -68.30 | -68.30 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
366.23 | 84.42 | -378.30 | -172.95 | -203.49 | -216.94 | -213.00 | -181.89 | -207.26 | -196.83 | -101.94 | -59.46 | -91.73 | -107.71 | -114.42 | -123.10 | -116.30 | -96.51 | -87.74 | -91.60 | -89.81 | -85.46 | -80.78 | -68.45 | -68.53 | -69.19 | -70.64 | -73.02 | -62.96 | -60.76 | -28.29 | -24.92 | 11.06 | 44.37 | 39.44 | 22.29 | 17.65 | 12.71 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 286.3 | 767.1 | 3592.5 | 3270.6 | 3950.2 | 2009.9 | - | - | - | - | - | 71.9 | 58.8 | 58.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.1 | 0.1 | 0.2 | 0.2 | 383.7 | 3592.5 | 3270.6 | 3950.2 | 2009.9 | - | - | - | - | - | - | 22.8 | 58.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.1 | 0.1 | 0.2 | 0.2 | 383.7 | 3592.5 | 3270.6 | 3950.2 | 2009.9 | - | - | - | - | - | - | 22.8 | 58.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Syros Pharmaceuticals, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Israel
Germany
Australia
Britain
Russia
China
France
Belgium
Canada
Bermuda
